Cellosaurus logo
expasy logo

Cellosaurus YUL-PR2 (CVCL_C8TK)

[Text version]
Cell line name YUL-PR2
Accession CVCL_C8TK
Resource Identification Initiative To cite this cell line use: YUL-PR2 (RRID:CVCL_C8TK)
Comments Selected for resistance to: ChEBI; CHEBI_195559; Poziotinib (HMB781-36B).
Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
Sequence variations
  • Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771delinsPheHis (N771delinsFH); Zygosity=Unspecified (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_C8TI (YUL-0019)
Category Cancer cell line
Publications

PubMed=35820397; DOI=10.1016/j.ccell.2022.06.006; PMCID=PMC9667883
Elamin Y.Y., Robichaux J.P., Carter B.W., Altan M., Tran H., Gibbons D.L., Heeke S., Fossella F.V., Lam V.K., Le X.-N., Negrao M.V., Nilsson M.B., Patel A., Vijayan R.S.K., Cross J.B., Zhang J.-J., Byers L.A., Lu C., Cascone T., Feng L., Luthra R., San Lucas F.A., Mantha G., Routbort M.J., Blumenschein G.R. Jr., Tsao A.S., Heymach J.V.
Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Cancer Cell 40:754-767.e6(2022)

Cross-references
Encyclopedic resources Wikidata; Q123033992
Entry history
Entry creation05-Oct-2023
Last entry update19-Dec-2024
Version number3